AbstractChildren with chronic kidney disease (CKD) have difficulty achieving normal growth due to severe alterations in the growth hormone (GH) and insulin-like growth factor (IGF-1) axis. Recombinant human growth hormone (rhGH) therapy (GH). It encourages long-term growth and allows children with CKD to reach normal height.It has been demonstrated to be both safe and effective. After a kidney transplant, growth retardation may remain. Multiple variables, such as steroid use, impaired renal function, and an aberrant GH axis, have contributed to this condition.